Overview

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2017-02-23

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and at elevated risk of cardiovascular events.

Phase:

Phase 4

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

The George Institute for Global Health, Australia

Treatments:

Canagliflozin